MBRX vs. CARA, TENX, COCP, ATHA, GOVX, MIRA, CYTH, BTAI, APRE, and BFRG
Should you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Cara Therapeutics (CARA), Tenax Therapeutics (TENX), Cocrystal Pharma (COCP), Athira Pharma (ATHA), GeoVax Labs (GOVX), MIRA Pharmaceuticals (MIRA), Cyclo Therapeutics (CYTH), BioXcel Therapeutics (BTAI), Aprea Therapeutics (APRE), and Bullfrog AI (BFRG). These companies are all part of the "pharmaceutical products" industry.
Moleculin Biotech vs.
Cara Therapeutics (NASDAQ:CARA) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, community ranking, dividends, analyst recommendations, profitability, earnings and valuation.
Moleculin Biotech has lower revenue, but higher earnings than Cara Therapeutics.
Cara Therapeutics received 439 more outperform votes than Moleculin Biotech when rated by MarketBeat users. Likewise, 72.50% of users gave Cara Therapeutics an outperform vote while only 50.00% of users gave Moleculin Biotech an outperform vote.
Cara Therapeutics has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500.
Cara Therapeutics presently has a consensus price target of $27.84, suggesting a potential upside of 498.71%. Moleculin Biotech has a consensus price target of $24.00, suggesting a potential upside of 1,176.60%. Given Moleculin Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Cara Therapeutics.
44.7% of Cara Therapeutics shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 3.1% of Cara Therapeutics shares are held by company insiders. Comparatively, 7.1% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Moleculin Biotech has a net margin of 0.00% compared to Cara Therapeutics' net margin of -1,099.76%. Moleculin Biotech's return on equity of -157.44% beat Cara Therapeutics' return on equity.
In the previous week, Moleculin Biotech had 1 more articles in the media than Cara Therapeutics. MarketBeat recorded 2 mentions for Moleculin Biotech and 1 mentions for Cara Therapeutics. Moleculin Biotech's average media sentiment score of 0.53 beat Cara Therapeutics' score of 0.50 indicating that Moleculin Biotech is being referred to more favorably in the news media.
Summary
Moleculin Biotech beats Cara Therapeutics on 11 of the 15 factors compared between the two stocks.
Get Moleculin Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Moleculin Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:MBRX) was last updated on 1/21/2025 by MarketBeat.com Staff
Free MBRX Stock Alerts